CDC37 and cancer: Several Hsp90–Cdc37 disruptors, including DCZ3112, celastrol, and FW-04-806, have demonstrated promising in vivo antitumor efficacy in xenograft models, underscoring their potential as next-generation cancer therapeutics.47,57,73 However, despite these encouraging preclinical results, comprehensive pharmacokinetic (PK) profiling for many of these compounds remains limited.